Kornimate/medical-research-clean huggingface dataset:
tdcs and female urinary incontinence

Conditions: Urinary Incontinence

Summary: urinary incontinence (ui) is defined as any involuntary loss of urine and can be divided into three types: urgency, stress and mixed. pelvic floor exercises are considered the main non pharmacological choice for ui treatment. its mechanisms are not fully understood, however there are some evidence that central mechanisms play an important role in the continence control. in this context, neuromodulatory techniques, such as transcranial direct current stimulation (tdcs), that address cortical targets has been demonstrated promising results in different health conditions. however, few studies have investigated the efficacy of adding tdcs to exercise therapies for women with ui.


Eligibility criteria:
inclusion criteria: * complaining of urinary loss * seeking care for urinary incontinence exclusion criteria: * grade iii vaginal dystopias * intrapelvic tumors * cardiac pacemaker or other implanted devices * current pregnancy * urinary tract infections * previous treatment with tdcs
a pilot study of riluzole in patients with post traumatic stress disorder (ptsd)

Conditions: PTSD

Summary: this open label study will evaluate the safety and efficacy of riluzole in patients with ptsd. patients will receive riluzole 50mg twice per day orally for 12 weeks as outpatient, with a one month follow up at week 16.


Eligibility criteria:
inclusion criteria: * male or female subjects between the ages of 18-75 years; * able to provide written informed consent; * current post traumatic stress disorder, as determined by the clinician administered scale for ptsd, or the presence of sub-threshold ptsd. individuals with sub-threshold ptsd will be included at the discretion of the pi; * clinician administered ptsd scale (caps) score of 23 or higher; * be able to understand and speak english. * subjects taking fda-approved antidepressant medications may enter the study if they have been on a stable dose for at least 4 weeks prior to starting the study drug. exclusion criteria: * breastfeeding women and pregnant women, or women of child bearing potential who are not using a medically accepted means of contraception (to include oral, injectable, or implant birth control, condom, diaphragm with spermicide, intrauterine device, tubal ligation, abstinence, or partner with vasectomy); * current, ongoing serious suicidal risk as assessed by evaluating investigator or by scoring 5 or more on the item-10 of the madrs. * unstable medical illness as determined by the investigator; * patients with schizophrenia or schizoaffective disorders (current or past); * substance use disorder during the 3 months prior to screening; except for cannabis and alcohol use disorders. * clinical evidence of untreated hypothyroidism; * patients with any evidence of clinically significant liver abnormalities, or any liver transaminase level \> 1.5 x uln at initial screening, or \> 5 x uln during treatment; * axis ii personality disorders that are the primary purpose of treatment, or would interfere with a patient's safety or compliance, as determined by the investigator during open-ended psychiatric interview; * patients currently being treated for a respiratory disorder (including asthma or copd); * for participants over the age of 60, evidence of dementia as determined by the st. luis university mental status exam (slums; participants with total scores less than or equal to 20 will be excluded and referred to their primary care physician for follow-up/dementia evaluation); structured psychotherapy focused on treatment of ptsd is exclusionary unless the subject has had at least 8 weeks of treatment prior to starting the study medication;
proof of concept of model based cardiovascular prediction

Conditions: Cardiovascular Modeling; Aortic Coarctation; Aortic Valve Disease; Cardiovascular MRI

Summary: cardioproof is a proof-of-concept project that consolidates the outcomes of previous virtual physiological human (vph) projects and checks the applicability and effectiveness of available predictive modelling and simulation tools, validating them in interrelated clinical trials conducted in three european centres of excellence in cardiac treatment (from germany, italy and the uk). cardioproof focuses on patients with aortic valve disease and aortic coarctation, which, if left untreated, can ensue irreversible heart failure. as a result treatment becomes mandatory, but optimum timing and the best type of treatment still remain difficult to determine. with more than 50.000 interventions per year within the eu, the diseases addressed by cardioproof have a significant socio-economic impact. present clinical guidelines are highly complex and rely mostly on imaging diagnostics and clinical parameters, without benefiting, as yet, from patient-specific disease modelling based prediction. cardioproof goes beyond the current state of the art by conducting validation trials aimed at covering and comparing the complete spectrum of cardiovascular treatment, predicting the evolution of the disease and the immediate and mid-term outcome of treatment. operational clustering is going to provide a seamless clinical solution that applies different modeling methods to realize the potential of personalised medicine taking into account user-friendliness as a key component of clinical usability. cardioproof's goal is to provide first-hand data on comparative cost-effectiveness and clinical efficacy of the most advanced vph approaches compared to conventional diagnostics and treatment algorithms, thus accelerating the deployment of vph methods in clinical environments, and bring to maturity holistic patient-specific computer-based predictive models and simulations.


Eligibility criteria:
inclusion criteria: * patients with the need for surgical or interventional treatment with aortic coarctation * patients with the need for aortic valve disease surgery * both according to current treatment guidelines exclusion criteria: * contraindications for mri

Keywords: cardiovascular modeling aortic coarctation aortic valve disease
examining the impact of exercise training on vascular dysfunction in individuals with mental health disorders - study 3

Conditions: Peripheral Vascular Diseases

Summary: the purpose of this research study is to examine the effect of various forms of exercise training on blood vessel function in healthy individuals as well as individuals with mental health disorders (posttraumatic stress disorder (ptsd) and/or generalized anxiety disorder (gad)).

study #3 is made up of five sessions done on five separate days and the entire study can be completed in as little as 14 weeks. all testing sessions will take place at the exercise physiology research laboratory. volunteers will be asked to participate in one initial testing session (visit 1) lasting \< 1 hour that will help make them more familiar with the study equipment and procedures, determine body measures (height, weight, body fat), determine the maximum strength of their forearm and calf, and require one blood draw. the following two testing sessions (visits 2 and 3) with each session lasting between 2-3 hours that will involve multiple tests designed to determine the health of their blood vessels. for visit #2 they will be randomly given either antioxidant pills or placebo pills to determine the effect of oxidants on blood vessel health. for visit #3, they will be given whatever set of pills (antioxidant or placebo) that they did not receive during visit #2. also include two additional testing days (visits 5 and 6) that are identical to visits #2 and #3, two visits to test endurance or strength prior to and after the exercise training (visit 4 and 7), and ten weeks of exercise training (done 3-5 days per week). the exercise training will include one of two weight lifting programs that differ based on the amount of weight lifted (heavy vs moderate weight).

Eligibility criteria:
inclusion criteria: * apparently healthy and free of overt cardiovascular, pulmonary, or metabolic disease * for ptsd group, a score of ≥ 33 on pcl-5 checklist * for gad group, a score of ≥ 10 on the gad-7 self-report scale and \< 33 on the pcl-5 checklist * for healthy control group, a score of ≤ 10 on the gad-7 self-report scale and \< 33 on the pcl-5 checklist exclusion criteria: * taking medications that could influence cardiovascular function * current smokers who have recently quit smoking * illicit drug use or excessive alcohol consumption * pregnant women * significant calorie restriction or vitamin/mineral deficiencies * limited english proficiency

Keywords: cardiovascular disease vascular function ptsd gad oxidant
understanding individual listening strategies

Conditions: Hearing Loss, Sensorineural

Summary: the goal of this clinical trial is to learn if hearing aid settings that are customized to individual listening strategies result in better speech understanding than non-customized hearing aid settings. the main question it aims to answer is: do customized hearing aid settings result in better speech understanding? researchers will compare hearing aid settings that match individual listening strategy to a general setting. participants will: wear hearing aids for a 2-hour visit to our laboratory. listen to some sentences in noise and repeat the sentences they hear, with two different hearing aid settings listen to some sentences in noise and rate how understandable they think those sentences are, with two different hearing aid settings

participants will complete standard clinical hearing evaluations and a listening profile test to evaluate their individual listening strategy. hearing aids will then be programmed either based on their clinical hearing evaluations alone using typical hearing aid settings or based on their hearing test with settings further adjusted to account for their individual listening strategies.

Eligibility criteria:
inclusion criteria: * sensorineural hearing loss exclusion criteria: * montreal cognitive assessment \< 23 points

Keywords: speech recognition hearing aids
topotecan, vincristine, and doxorubicin in treating young patients with refractory stage 4 neuroblastoma

Conditions: Neuroblastoma

Summary: rationale: drugs used in chemotherapy, such as topotecan, vincristine, and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. giving more than one drug (combination chemotherapy) may kill more tumor cells. purpose: this phase ii trial is studying how well giving topotecan together with vincristine and doxorubicin works in treating young patients with refractory stage 4 neuroblastoma.

objectives: primary * assess whether treatment with topotecan hydrochloride, vincristine, and doxorubicin hydrochloride can achieve a satisfactory response rate in pediatric patients with stage 4 neuroblastoma that failed to respond to rapid first-line treatment. secondary * determine time to progression in these patients. * determine the toxicity of this regimen in these patients. outline: this is a multicenter, open-label study. patients receive topotecan hydrochloride iv over 30 minutes on days 1-5 and vincristine iv continuously and doxorubicin hydrochloride iv continuously over 48 hours on days 5 and 6. patients also receive filgrastim (g-csf) subcutaneously beginning on day 9 and continuing until blood counts recover. treatment repeats every 21-28 days for 2 courses in the absence of disease progression or unacceptable toxicity. patients who achieve partial response (pr) after two courses of treatment receive an additional two courses. patients who achieve complete response or very good pr are treated according to the standard therapy in protocol siop-europe- hr-nbl-1. patients who fail to achieve pr after 2 courses receive further treatment at the physician's discretion. patients are followed periodically for at least 3 years. projected accrual: a total of 63 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of stage 4 neuroblastoma * failed to achieve adequate metastatic partial response after first-line therapy while enrolled on protocol siop-europe-hr-nbl-1 patient characteristics: * neutrophil count \> 1,000/mm³ * platelet count ≥ 100,000/mm³ * creatinine ≤ 1.36 mg/dl * bilirubin ≤ 2.92 mg/dl * ast and alt \< 2.5 times upper limit of normal * glomerular filtration rate ≥ 60 ml/min * normal cardiac function on echocardiography * no severe organ dysfunction * no active hepatitis c or hepatitis b virus positivity * no hiv infection prior concurrent therapy: * no anti-tumor chemotherapy within the past 10 days * no radiotherapy within the past 30 days * no other investigational drugs within the past 30 days * no prior doxorubicin hydrochloride

Keywords: recurrent neuroblastoma disseminated neuroblastoma
titrated quantitative conjunctival provocation test (tqcpt)

Conditions: Allergic Rhinitis

Summary: the clinical relevance of an allergen-specific sensitization is proven e.g., by allergen challenge tests in clinical routine. several protocols for different challenge tests such as nasal (npt), bronchial (bpt) or conjunctival provocation test (cpt) have been proposed. beneath others, the cpt is broadly used in both clinical trials and routine because of its feasibility. however, there is no internationally harmonized standard regarding the clinical interpretation of cpt results as well as a lack of validation of a specific outcome score. therefore, this trial aims to investigate and validate a new scoring system for cpt results in order to provide this test as a useful method in future clinical trials.

of 33 patients who had been initially screened, ten patients did not fulfill all of the inclusion criteria mentioned hereafter. thus, 23 patients aged 18 to 67 years having a birch and/or grass pollen allergy were included in the analysis. the study is in line with the declaration of helsinki and is approved by the responsible ethics committee (ff 118/2012 (4 december 2012); landesärztekammer hessen, frankfurt, germany). all participating patients are informed of the nature and objectives of the study and signed an informed consent document. the cpt is conducted using standardized and registered allergen extracts (alk- abelló, hørsholm, denmark). at the first visit, a titrated quantitative cpt (tqcpt) is performed according to a standardized protocol. in case of a positive test result, cpt-results are to be confirmed at a re-challenge one week later. the final cpt takes place 3 to 4 weeks after the 2nd (confirmatory) challenge for analyzing the primary objective of the trial: reproducibility of the cpt symptom score. furthermore, objective evaluation of the clinical reactions after the tqcpt is documented using a matlab software program to calculate the degree of redness in percent. this is then correlated with the (subjective) main investigators' evaluations and with the external observer's evaluations.

Eligibility criteria:
inclusion criteria: * moderate to severe allergic rhinoconjunctivitis (arc) symptoms in preceding two years -intake of anti-allergic medication in the preceding two years -positive test result in skin prick test (spt) (wheal size at least 3 mm larger than the negative control). - * retrospective global symptoms score (≥5 out of 12) exclusion criteria: * acute diseases of the eye or of the nose/nasal sinuses, * persistent allergy * intake of concomitant (antiallergic) medication prior to cpt-challenges * cpt score ≥3 during the examination of the control (non-challenged eye) at baseline

Keywords: titrated quantitative conjunctival provocation test
effect of su-man formula massage oil acupressure on sleep quality and anxiety in patients with insomnia

Conditions: Insomnia

Summary: the present study predict that su-man formula massage oil acupressure can improved sleep quality.

about 7% person in general population became as insomnia every year, and that has 30% person due to insomnia induces other symptoms such as anxiety. in addition, the incidence of insomnia in the female is 50% more than in the male. insomnia belong to the scope of bù-mèi in traditional chinese medicine (tcm). tcm consider that the cause of insomnia is due to unbalance between yin and yang, and acupressure can treat insomnia. several studies report that aromatherapy can enhance sleepy. therefore, the purpose of the present study was to assess the therapeutic effect of su-man formula massage oil associates with acupressure on sleepy quality and anxiety lysis. a total 40 patients with insomnia divided into two groups, each group is 20 patients as follows: 1) control group, using bergamot massage oil apply to gv20, gv24 sp6, ht7 and pc6 acupoints, and massage for 10 times before sleep continuously 28 days; 2) test group, using su-man formula massage oil ap-ply to gv20, gv24, sp6, ht7 and pc6 acupoints, and massage for 10 times before sleep continuously 28 days. the primary outcome measurement is the chinese version of insomnia severity in-dex(isi-c), pittsburgh sleep quality index (cpsqi), and beck anxiety inventory(bai); the secondary outcome measure is the changes of meridian energy.

Eligibility criteria:
inclusion criteria: * women who has poor sleep status attaining a score of 5 on the chinese pittsburgh sleep quality index * 20-50 years exclusion criteria: * having asthma or any diseases involving notable organ damage (e.g., heart, lungs, liver, or kidney failure or severe olfactory dysfunction) * being pregnant * being breastfeeding * have reached menopause * taking any medicine for improving sleep or anxiolytic drugs * be allergic to the oil that this study used. * having skin problem over the applying area, * having smoking and alchol drinking habit * inability to participate in the full course of the intervention courses

Keywords: su-man formula massage oil acupressure meridian energy insomnia
sgs: a structured treatment and teaching programme for elderly patients with diabetes mellitus

Conditions: Diabetes Mellitus

Summary: it was the aim of the study to develop and evaluate the effectiveness of a new structured teaching and training programme for elderly patients with diabetes mellitus (sgs) and insulin therapy.

patient education has become an integral part of any diabetes therapy in germany. but elderly people are often not able to follow the variety of topics comprising standard treatment and training programmes for insulin-treated patients with type 2 diabetes mellitus due to geriatric syndromes and neuropsychological deficits. therefore, treatment of elderly diabetics should focus on individual therapeutic goals, which reflect reduced life expectancy and quality of life. it was the aim of the study to develop and evaluate the effectiveness of a new structured teaching and training programme for elderly patients with diabetes mellitus (sgs) and insulin therapy. the high prevalence of cognitive impairment and affective disorders requires special pedagogical methods as well as adapted contents. for example the advantages of physical activity, the frequent existence of malnutrition, urinary incontinency or heart failure are taken into consideration. contents are transmitted in a practical and daily-living oriented way. the programme comprises 7 education lessons of 45 minutes duration implying the education units: diabetes mellitus, nutrition, treatment strategies, self-monitoring and complications focussing the diabetic foot syndrome. the effectiveness of the new structured treatment and teaching programme sgs was evaluated in a multicenter prospective randomised controlled trial. diabetic patients admitting one of 18 study centres in germany with at least one geriatric syndrome, comorbidity and older than 65 years were randomised either to the new sgs programme or to the standard treatment programme for patients with type 2 diabetes mellitus. before and 6 month after participation in the structured treatment programmes the outcome quality was evaluated using structured questionnaires. we assessed hba1c, skills of diabetes self-management, diabetes knowledge, treatment satisfaction, acute and late complications, neuropsychological status, diabetes mediation, activities of daily living and need of social service. the main treatment goal was maintenance of autonomy and quality of life in elderly people, as well as prevention of catabolism, frailty and acute complications.

Eligibility criteria:
inclusion criteria: * age older than 65 years, at least more than one other diagnosis than diabetes, at least one geriatric syndrome exclusion criteria: * myocardial infarction, apoplexy within the last 2 weeks before planned enrolment

Keywords: diabetes mellitus, structured treatment and teaching, education, elderly patients, geriatrics
effect of mother dha supplementation on premature newborn.

Conditions: Oxidative Stress

Summary: to date, the investigations in the field of the supplementation with dha in premature babies have been focused on the study of neuronal and visual development, giving place to contradictory and ambiguous results, because they did not consider in many cases important aspects of this supplementation, such as the mother´s diet, dose, duration, etc., and precise studies have not been performed in the field of the oxidative damage, inflammation and bone development in this population. hypothesis: if the composition of the mother´s milk is modified on the basis of her diet, a mother supplementation with high doses of dha will increase proportionally the levels of this fatty acid in her milk, fact that will allows the premature newborn child receive a major dose of this fatty acid, and therefore this way, we will manage to improve the neuronal and visual development and to take part on the inflammatory process, oxidative damage and its evolution, together with the development or bone mass increase in the premature baby. aims: overall we aim to evaluate in a multidisciplinary way the effect of a mother supplementation during the lactation with high doses of dha on the development and wellness of the premature newborn children. we try to deepen into the effect on the neuronal and visual development and to study, for the first time, the effect on the oxidative damage, pro- and antiinflammatory citoquines activity and bone metabolism in this group of newborn babies.

experimental design: we will establish two groups of premature newborn children (\<34 weeks) (n=40). the mothers of one of the groups of premature newborn children will receive an oral supplementation by means of capsules with high dose of dha (900 mg/day) during the lactation (minimum period of 3 months). in addition, all the groups will be underwent to a nutritional surveillance (a follow-up of 48 hours and a questionnaire of frequency of consumption) and will be given nutritionally-balanced diets, insisting especially in the suitable consumption of fish (4 portions/week). blood samples will be obtained in all the groups at the birth moment, at the week 40 of gestational age corrected in the groups of premature babies and at the end of the lactation in all the groups (minimum 3 months).we will obtain samples of mother´s milk (colostrum, transition and mature milk). in these samples we will study bone turnover biomarkers, pro - and anti-inflammatory citoquines and markers of aggression oxidative damage. in addition, we will perform psychomotor and visual development tests in the newborn children.

Eligibility criteria:
inclusion criteria: * preterm neonate, gestational age 30-34, paeg (\>p10, \<p95), no pathologies. exclusion criteria: * lactose intolerance, systemic illness, multiple gestation, cromosomopathies, antibacterial therapy.

Keywords: neonates, dha